Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., . . . Moreau, P. (2016). Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood.
Chicago Style CitationAvet-Loiseau, Hervé, et al. "Carfilzomib Significantly Improves the Progression-free Survival of High-risk Patients in Multiple Myeloma." Blood 2016.
Cita MLAAvet-Loiseau, Hervé, et al. "Carfilzomib Significantly Improves the Progression-free Survival of High-risk Patients in Multiple Myeloma." Blood 2016.
Atenció: Aquestes cites poden no estar 100% correctes.